Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AbbVie is conducting a study titled ‘Special Drug Use-results Survey of Duodopa Enteral Solution in Patients With Parkinson’s Disease’ to evaluate the safety and efficacy of Duodopa for long-term use in real-world settings. The primary objective is to understand how this treatment performs over 104 weeks in patients with Parkinson’s disease.
The study focuses on Duodopa, an enteral solution designed to manage symptoms of Parkinson’s disease by delivering a continuous dose of levodopa/carbidopa directly to the small intestine, aiming to improve motor function and quality of life.
This observational cohort study is prospective in nature, meaning it follows patients over time to observe outcomes. There is no random allocation or masking involved, as the primary goal is to gather data on real-world usage.
The study began on September 12, 2016, with the latest update submitted on August 7, 2025. These dates are crucial as they indicate the study’s progression and the most recent data available for analysis.
The ongoing study could influence AbbVie’s stock performance by showcasing the potential of Duodopa in treating Parkinson’s disease, potentially boosting investor confidence. This development is significant in the competitive landscape of Parkinson’s treatments, where innovation is key.
The study is currently active but not recruiting, with further details accessible on the ClinicalTrials portal.